Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins

References

• Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001;61:1835–811Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001;61:1835–81
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, McNamara JR, Tayler T. et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002; 90:689–962Schaefer EJ, McNamara JR, Tayler T. et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002; 90:689–96
   PubMed Web of Science ®Google Scholar
• Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303–283Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303–28
   PubMed Web of Science ®Google Scholar
• Schuster H. Rosuvastatin – a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10–40 mg doses in dyslipidemic patients. Cardiology 2003;99:126–394Schuster H. Rosuvastatin – a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10–40 mg doses in dyslipidemic patients. Cardiology 2003;99:126–39
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Rizos E, Kostapanos M. et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006;22:1123–315Milionis HJ, Rizos E, Kostapanos M. et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006;22:1123–31
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bertolami M, Hernandez Garcia HR. et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 2006;151:975–96Ballantyne CM, Bertolami M, Hernandez Garcia HR. et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 2006;151:975–9
   PubMed Web of Science ®Google Scholar
• Schuster H, Barter PJ, Stender S. et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin TherapY (MERCURY I) study. Am Heart J 2004;147:705–137Schuster H, Barter PJ, Stender S. et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin TherapY (MERCURY I) study. Am Heart J 2004;147:705–13
   PubMed Web of Science ®Google Scholar
• Leiter LA, Rosenson RS, Stein E. et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 2007;194:154–648Leiter LA, Rosenson RS, Stein E. et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 2007;194:154–64
   PubMed Web of Science ®Google Scholar
• Bergheanu SC, Van Tol A, Dallinga-Thie GM. et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin 2007;23:2235–409Bergheanu SC, Van Tol A, Dallinga-Thie GM. et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin 2007;23:2235–40
   PubMed Web of Science ®Google Scholar
• Jukema JW, Liem AH, Dunselman PH. et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin 2005;21:1865–7410Jukema JW, Liem AH, Dunselman PH. et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin 2005;21:1865–74
   PubMed Web of Science ®Google Scholar
• Dietzen DJ, Page KL, Tetzloff TA. et al. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase blunts factor VIIa/tissue factor and prothrombinase activities via effects on membrane phosphatidylserine. Arterioscler Thromb Vasc Biol 2007;27:690–611Dietzen DJ, Page KL, Tetzloff TA. et al. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase blunts factor VIIa/tissue factor and prothrombinase activities via effects on membrane phosphatidylserine. Arterioscler Thromb Vasc Biol 2007;27:690–6
   PubMed Web of Science ®Google Scholar
• Ii M, Nishimura H, Kusano KF. et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005;112:93–10212Ii M, Nishimura H, Kusano KF. et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005;112:93–102
   PubMed Web of Science ®Google Scholar
• Pelat M, Dessy C, Massion P. et al. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003;107:2480–613Pelat M, Dessy C, Massion P. et al. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003;107:2480–6
   PubMed Web of Science ®Google Scholar
• Van der Greef J, Hankemeier T, McBurney RN. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 2006;7:1087–9414Van der Greef J, Hankemeier T, McBurney RN. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 2006;7:1087–94
   PubMed Web of Science ®Google Scholar
• Van der Greef J, McBurney RN. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 2005;4:961–715Van der Greef J, McBurney RN. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 2005;4:961–7
   PubMed Web of Science ®Google Scholar
• Van der Greef J, Martin S, Juhasz P. et al. The art and practice of systems biology in medicine: mapping patterns of relationships. J Proteome Res 2007;6:1540–5916Van der Greef J, Martin S, Juhasz P. et al. The art and practice of systems biology in medicine: mapping patterns of relationships. J Proteome Res 2007;6:1540–59
   PubMed Web of Science ®Google Scholar
• Van der Greef J, Davidov E, Verheij ER, et al. Metabolic profiling: its role in biomarker discovery and gene function analysis. In: Harrigan GG, Goodacre R, eds. The role of Metabolomics in Systems Biology, a New Vision for Drug Discovery and Development. Boston: Kluwer Academic Publishing, 2003.17Van der Greef J, Davidov E, Verheij ER, et al. Metabolic profiling: its role in biomarker discovery and gene function analysis. In: Harrigan GG, Goodacre R, eds. The role of Metabolomics in Systems Biology, a New Vision for Drug Discovery and Development. Boston: Kluwer Academic Publishing, 2003.
   Google Scholar
• Huck SW. Analyses of variance with repeated measures. In: Reading Statistics and Research, Chapter 14. Boston: Pearson Education, 2008.18Huck SW. Analyses of variance with repeated measures. In: Reading Statistics and Research, Chapter 14. Boston: Pearson Education, 2008.
   Google Scholar
• Jackson JE. A User's Guide to Principal Components. New York: John Wiley, 199119Jackson JE. A User's Guide to Principal Components. New York: John Wiley, 1991
   Google Scholar
• Brereton RG. Chemometrics Data Analysis for the Laboratory and Chemical Plant. Chichester. UK: John Wiley, 200720Brereton RG. Chemometrics Data Analysis for the Laboratory and Chemical Plant. Chichester. UK: John Wiley, 2007
   Google Scholar
• Vandengiste BGM, Massart DL, Buydens LMC. et al. Handbook of Chemometrics and Qualimetrics. Amsterdam: Elsevier, 199821Vandengiste BGM, Massart DL, Buydens LMC. et al. Handbook of Chemometrics and Qualimetrics. Amsterdam: Elsevier, 1998
   Google Scholar
• Park TS, Panek RL, Rekhter MD. et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 2006;189:264–7222Park TS, Panek RL, Rekhter MD. et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 2006;189:264–72
   PubMed Web of Science ®Google Scholar
• Nelson JC, Jiang XC, Tabas I. et al. Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006;163:903–1223Nelson JC, Jiang XC, Tabas I. et al. Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006;163:903–12
   PubMed Web of Science ®Google Scholar
• Jiang XC, Paultre F, Pearson TA. et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000;20:2614–1824Jiang XC, Paultre F, Pearson TA. et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000;20:2614–18
   PubMed Web of Science ®Google Scholar
• Schlitt A, Blankenberg S, Yan D. et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) 2006;3:525Schlitt A, Blankenberg S, Yan D. et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) 2006;3:5
   PubMed Web of Science ®Google Scholar
• Oestvang J, Bonnefont-Rousselot D, Ninio E. et al. Modification of LDL with human secretory phospholipase A(2) or sphingomyelinase promotes its arachidonic acid-releasing propensity. J Lipid Res 2004;45:831–826Oestvang J, Bonnefont-Rousselot D, Ninio E. et al. Modification of LDL with human secretory phospholipase A(2) or sphingomyelinase promotes its arachidonic acid-releasing propensity. J Lipid Res 2004;45:831–8
   PubMed Web of Science ®Google Scholar
• Kleemann R, Princen HM, Emeis JJ. et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003;108:1368–7427Kleemann R, Princen HM, Emeis JJ. et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003;108:1368–74
   PubMed Web of Science ®Google Scholar
• Arimoto I, Saito H, Kawashima Y. et al. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res 1998;39:143–5128Arimoto I, Saito H, Kawashima Y. et al. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res 1998;39:143–51
   PubMed Web of Science ®Google Scholar
• Bolin DJ, Jonas A. Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem 1996;271:19152–829Bolin DJ, Jonas A. Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem 1996;271:19152–8
   PubMed Web of Science ®Google Scholar
• Puri V, Jefferson JR, Singh RD. et al. Sphingolipid storage induces accumulation of intracellular cholesterol by stimulating SREBP-1 cleavage. J Biol Chem 2003;278:20961–7030Puri V, Jefferson JR, Singh RD. et al. Sphingolipid storage induces accumulation of intracellular cholesterol by stimulating SREBP-1 cleavage. J Biol Chem 2003;278:20961–70
   PubMed Web of Science ®Google Scholar
• Worgall TS, Juliano RA, Seo T. et al. Ceramide synthesis correlates with the posttranscriptional regulation of the sterol-regulatory element-binding protein. Arterioscler Thromb Vasc Biol 2004;24:943–831Worgall TS, Juliano RA, Seo T. et al. Ceramide synthesis correlates with the posttranscriptional regulation of the sterol-regulatory element-binding protein. Arterioscler Thromb Vasc Biol 2004;24:943–8
   PubMed Web of Science ®Google Scholar
• Smith EB. Intimal and medial lipids in human aortas. Lancet 1960;1:799–80332Smith EB. Intimal and medial lipids in human aortas. Lancet 1960;1:799–803
   PubMed Web of Science ®Google Scholar
• Noel C, Marcel YL, Davignon J. Plasma phospholipids in the different types of primary hyperlipoproteinemia. J Lab Clin Med 1972;79:611–2133Noel C, Marcel YL, Davignon J. Plasma phospholipids in the different types of primary hyperlipoproteinemia. J Lab Clin Med 1972;79:611–21
   PubMed Web of Science ®Google Scholar
• Schissel SL, Jiang X, Tweedie-Hardman J. et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem 1998;273:2738–4634Schissel SL, Jiang X, Tweedie-Hardman J. et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem 1998;273:2738–46
   PubMed Web of Science ®Google Scholar
• Jeong T, Schissel SL, Tabas I. et al. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 1998;101:905–1235Jeong T, Schissel SL, Tabas I. et al. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 1998;101:905–12
   PubMed Web of Science ®Google Scholar
• Peura P, Martikainen J, Soini E. et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008;24:1823–3236Peura P, Martikainen J, Soini E. et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008;24:1823–32
   PubMed Web of Science ®Google Scholar
• Laaksonen R, Katajamaa M, Paiva H. et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 2006;1:e9737Laaksonen R, Katajamaa M, Paiva H. et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 2006;1:e97
   PubMed Web of Science ®Google Scholar